125 related articles for article (PubMed ID: 11422606)
61. Factors influencing plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic children and adults.
Lanchote VL; Bonato PS; Campos GM; Rodrigues I
Ther Drug Monit; 1995 Feb; 17(1):47-52. PubMed ID: 7725376
[TBL] [Abstract][Full Text] [Related]
62. Effects of concomitant antiepileptic drugs on serum carbamazepine concentration in epileptic patients: quantitative analysis based on extracellular water volume as a transforming factor.
Fukuoka N; Tsukamoto T; Uno J; Kimura M; Morita S
Yakugaku Zasshi; 2003 Jan; 123(1):35-42. PubMed ID: 12607943
[TBL] [Abstract][Full Text] [Related]
63. Decreased bioavailability of carbamazepine suppository after its intrarectal and intracolostomal administration to rectal-resected or colostoma-constructed rabbits.
Nagasawa K; Nakanishi H; Yamamoto R; Kintsuji S; Fujimoto S
Int J Pharm; 2002 Jul; 241(2):375-84. PubMed ID: 12100865
[TBL] [Abstract][Full Text] [Related]
64. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
Park PW; Seo YH; Ahn JY; Kim KA; Park JY
J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
[TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
[TBL] [Abstract][Full Text] [Related]
66. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
[TBL] [Abstract][Full Text] [Related]
67. Altered ratio of carbamazepine-10,11-epoxide/carbamazepine in plasma of children: evidence of anticonvulsant drug interaction.
Schoeman JF; Elyas AA; Brett EM; Lascelles PT
Dev Med Child Neurol; 1984 Dec; 26(6):749-55. PubMed ID: 6440824
[TBL] [Abstract][Full Text] [Related]
68. A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy.
Vovk T; Jakovljević MB; Kos MK; Janković SM; Mrhar A; Grabnar I
Biol Pharm Bull; 2010; 33(7):1176-82. PubMed ID: 20606310
[TBL] [Abstract][Full Text] [Related]
69. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
70. Steady-state serum concentrations of carbamazepine and valproic acid in obese and lean patients with epilepsy.
Suemaru K; Kawasaki H; Yasuhara K; Yao K; Furuno K; Kawakami Y; Araki H; Gomita Y; Oka E
Acta Med Okayama; 1998 Jun; 52(3):139-42. PubMed ID: 9661740
[TBL] [Abstract][Full Text] [Related]
71. Time-dependent influence of pentoxifylline on the pharmacokinetics of orally administered carbamazepine in human subjects.
Poondru S; Devaraj R; Boinpally RR; Yamsani MR
Pharmacol Res; 2001 Mar; 43(3):301-5. PubMed ID: 11401423
[TBL] [Abstract][Full Text] [Related]
72. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
Vaz J; Kulkarni C; David J; Joseph T
Indian J Exp Biol; 1998 Jan; 36(1):112-4. PubMed ID: 9536660
[TBL] [Abstract][Full Text] [Related]
73. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions.
Brewster ME; Anderson WR; Meinsma D; Moreno D; Webb AI; Pablo L; Estes KS; Derendorf H; Bodor N; Sawchuk R; Cheung B; Pop E
J Pharm Sci; 1997 Mar; 86(3):335-9. PubMed ID: 9050802
[TBL] [Abstract][Full Text] [Related]
74. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation.
Schäffler L; Bourgeois BF; Lüders HO
Epilepsia; 1994; 35(1):195-8. PubMed ID: 8112245
[TBL] [Abstract][Full Text] [Related]
75. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
[TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models.
Fortuna A; Alves G; Soares-da-Silva P; Falcão A
Epilepsy Res; 2013 Nov; 107(1-2):37-50. PubMed ID: 24050973
[TBL] [Abstract][Full Text] [Related]
77. Effect of vigabatrin on the pharmacokinetics of carbamazepine.
Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I; Llopis P
J Clin Pharm Ther; 2002 Dec; 27(6):427-30. PubMed ID: 12472982
[TBL] [Abstract][Full Text] [Related]
78. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
79. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
[TBL] [Abstract][Full Text] [Related]
80. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Andreasen AH; Brøsen K; Damkier P
Epilepsia; 2007 Mar; 48(3):490-6. PubMed ID: 17346248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
